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BPA - bisphenol A 27 
DCC - dextran-coated charcoal 28 
E2 - 17β-estradiol  29 
EDCs - endocrine disrupting chemicals 30 
EEQ - 17β-estradiol equivalent quantity 31 
ER - Estrogen receptor 32 
FSH - Follicle-stimulating hormone 33 
GH - Growth hormone 34 
ISO - International Organization for Standardization 35 
HELN - human uterine cervix carcinoma cells (HeLa) stably transfected with ERE-βGlob-Luc-36 
SVNeo and pSG5ERαpuro or pSG5ERβpuro plasmids (HELNα or HELNβ, respectively). 37 
HPLC - high-performance liquid chromatography  38 
LH - Luteinizing hormone 39 
MELN - breast cancer cells (MCF-7) stably transfected with ERE-βGlob-Luc-SVNeo plasmid. 40 
OECD - Organisation for Economic Co-operation and Development 41 
PCBs - polychlorinated biphenyls 42 
PFAA - perfluorinated alkyl acids 43 
POPs - persistent organic pollutants 44 
PP - precocious puberty 45 








Biological assays can evaluate the cumulative effect of a mixture, considering 52 
synergistic/antagonistic interactions and effects of unknown/unconsidered compounds. 53 
Therefore, their application could increase in the next years also to analyse biological samples.  54 
The aim of this review is to discuss the methodological approach and the application of 55 
estrogenic activity assays in human biological samples. 75 research articles were analysed and 56 
divided according to whether they used these assays: i) to quantify the level of estrogens and/or 57 
as a biomarker of estrogenic status ii) as a biomarker of exposure to endocrine disrupting 58 
chemicals (EDCs).  59 
For the first purpose, some authors extracted biological samples while others tested them 60 
directly without any treatment. The study of these methodologies outlined that the methodology 61 
applied influenced the specificity of analysis. The estrogenic activity biomarker was used to 62 
analyse physiological variations of estrogens, pediatric diseases, hormone-dependent diseases 63 
and estrogen suppression/enhancement after pharmaceutical treatments. 64 
For the second purpose, some authors extracted samples while others tested them directly, some 65 
authors divided endogenous estrogens from xenoestrogens while others tested samples without 66 
separation. The analysis of these methodologies outlined some limitations related to the 67 
efficiency of extraction and the incorrect separation of some compounds. The studies which 68 
applied this EDC biomarker showed that it was correlated with some EDCs, it varied according 69 
to the exposure of the population and it allowed the identification of some relationships 70 
between EDC exposure and breast cancer, type 1 diabetes and adverse health effects on 71 
children.  72 
In conclusion, the estrogenic activity of biological samples can be a useful tool: to quantify low 73 
levels of 17β-estradiol, to assess the combined effect of endogenous estrogens and 74 
xenoestrogens, to estimate the estrogenic status providing considerable insight into 75 
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physiological or pathological conditions, to evaluate EDC presence implementing the existing 76 
knowledge about EDC exposure and adverse health effects.  77 
 78 
Keywords: estrogenic activity, biological samples, EDC, exposure biomarker, hormone-79 
dependent diseases, adverse health effects. 80 
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1. Introduction 112 
The endocrine system is based on hormones, which are molecules produced by endocrine 113 
glands, organs and tissues and released into the blood. Once they reach cells and tissues, 114 
hormones can induce several effects through hormone receptors. Hormones are involved in 115 
complex signalling pathways, which regulate numerous development stages of human and 116 
animal life: foetal development, childhood and puberty. The endocrine system also controls 117 
several functions in adulthood such as reproduction, metabolism and thermal regulation, and it 118 
interacts with other systems such as nervous and immune systems (Bergman et al. 2013, 119 
Demeneix and Slama 2019). Therefore, a correct functioning of the endocrine system is crucial 120 
in order to ensure the correct regulation of numerous physiological processes and its 121 
dysfunction or perturbation can lead to several adverse health effects such as malformations, 122 
metabolic disorders, reduced fertility and cancer (Bergman et al. 2013, Kabir et al. 2015, 123 
Pamplona-Silva et al. 2018).  124 
Even if the endocrine system includes several different hormones, the scientific community 125 
focused in particular on estrogens because of their peculiar characteristics. Estrogens exert a 126 
crucial role in human organisms since they regulate menstrual/estrous reproductive cycles and 127 
they are also involved in more complex mechanisms such as the physiology of reproductive 128 
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organs and tissues (e.g., breast, ovary and endometrium), lipid metabolism, protein synthesis 129 
and diseases (e.g., cancer and neurodegenerative/cardiovascular diseases) (Kiyama and Wada-130 
Kiyama 2015). Moreover, estrogens play a critical role in the physiology and pathology of the 131 
immune system, and therefore they can influence the onset and the progression of some 132 
autoimmune diseases (Benagiano et al. 2019, Merrheim et al. 2020). 133 
The most important endogenous estrogens are 17β-estradiol (E2), estrone and estriol (Kiyama 134 
and Wada-Kiyama 2015) and their actions occur at very low concentrations (Pamplona-Silva 135 
et al. 2018). 136 
Due to their key role in the organism, the evaluation of estrogen levels can be helpful to 137 
understand and treat a wide range of physiological or clinical conditions in children as well as 138 
adults (Rosner et al. 2013). The least invasive methods to estimate estrogen levels are indirect 139 
methods which consist in tracking physiologic changes. These methods include monitoring 140 
basal body temperature, using tests of urine to detect ovulation, examining vaginal discharge 141 
and measuring other body changes, such as uterine length at pelvic sonography to evaluate 142 
female pubertal status (Bellem et al. 2011, Paris et al. 2002).  However, since they have a low 143 
specificity and sensitivity, indirect methods are generally coupled with direct methods such as 144 
immunoassays and spectrometry analysis which can quantify hormone levels in biological 145 
samples (e.g. saliva, blood, urine) (Bellem et al. 2011). Immunoassays measure hormones 146 
using the binding between antigen and antibody, which is amplified using different markers: 147 
radioisotope, enzyme, fluorescent or chemiluminescent labels (radioimmunoassay, enzyme 148 
immunoassay, fluorescence immunoassay, chemiluminescence immunoassay). Immunoassays 149 
are generally considered to be quite specific, but their sensitivity is often insufficient to detect 150 
low hormone levels and it seems that they tend to overestimate hormonal levels (Santen et al. 151 
2008). Moreover they are unable to measure different estrogens simultaneously (Bellem et al. 152 
2011) and they do not reflect the hormonal activity in the samples since they only quantify the 153 
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concentration of compounds that are structurally recognized by the antibody, thus neglecting 154 
the overall activity induced by compounds with the same action mechanism (Widschwendter 155 
et al. 2009). Mass spectrometry identifies and quantifies each chemical through its mass-to-156 
charge ratio after ionization (electron spray or electron impact ionization). Before the mass 157 
spectrometry analysis, the sample is generally prepared using a separation technique (gas 158 
chromatography or liquid chromatography). The tandem mass spectrometry, which is coupled 159 
with spectral analysis in multiple rounds, is accepted as the golden standard for hormone assays 160 
but it shows some limitations such as the expensive equipment needed and the technical 161 
complexity of the analysis, which involves several steps and thus requires a long time (Bellem 162 
et al. 2011). Immunoassays and mass spectrometry have been widely used for their specificity 163 
since they quantify the concentrations of specific hormones. However, their high specificity 164 
may oversimplify the physiological situation. The physiological hormonal activity is mainly 165 
based on the effect of a specific hormone, but it can also be induced by other hormones, 166 
hormone metabolites and growth factors. Also, it can be altered by exogenous substances. 167 
Therefore, in recent years bioassays have been used for hormonal activity quantification by an 168 
increasing number of authors. Bioassays are based on biological reactions that depend on the 169 
presence or absence of the hormone, but also on the presence of other substances, which can 170 
induce the same effect. For example, bioassays for estrogenic activity can detect the total 171 
estrogenic effect in human biological samples: they measure the activity of E2 but are also able 172 
to detect the activity induced by other estrogens such as estrone and estriol (Paris et al. 2002).   173 
In addition to estrogens, a great number of exogenous compounds can exert and modulate the 174 
estrogenic activity which can be measured by means of bioassays. These estrogenic compounds 175 
are part of a group of substances called endocrine disrupting chemicals (EDCs). The World 176 
Health Organization defined EDCs as “exogenous substances or mixtures that alter function(s) 177 
of the endocrine system and consequently cause adverse health effects in an intact organism, 178 
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or its progeny, or (sub) populations” (Damstra et al. 2002). EDCs are a highly heterogeneous 179 
group of natural (i.e., steroids and phytoestrogen) and synthesized chemicals (i.e., synthetic 180 
chemicals, plastics, plasticizers, pesticides, pharmaceutical agents) (Diamanti-Kandarakis et 181 
al. 2009, Kabir et al. 2015) which can interfere with the endocrine system in different ways: 182 
first, they can act directly by binding to hormone receptors. In particular, agonist EDCs can 183 
imitate hormones, thus producing over or under responses, while antagonist EDCs can block 184 
the response. Second, EDCs can indirectly interact with receptors as they can interfere with the 185 
synthesis, transport, metabolism and excretion of hormones (Hampl et al. 2016, Kabir et al. 186 
2015). These contaminants are ubiquitous in the environment and human exposure to them 187 
occurs in different ways, such as by inhalation (mainly in the working environment), ingestion 188 
of contaminated food and/or water and dermal contact through personal care products (Kabir 189 
et al. 2015). Since low doses of EDCs could be enough to induce effects - and exposure during 190 
specific lifetime periods could induce permanent adverse effects - EDCs may represent an 191 
alarming health and environmental problem.  192 
In this context, the assessment of EDC exposure appears crucial in order to monitor populations 193 
at higher risk of exposure and to understand the link between exposure and adverse health 194 
effects. In biological samples concentrations of EDCs (e.g., bisphenol A (BPA), phthalates, 195 
parabens, polychlorinated biphenyls (PCBs), perfluorinated compounds, polybrominated 196 
diphenyl ethers) and metabolites of EDCs (e.g., metabolites of pyrethroids, insecticides, 197 
pesticides, phthalates) have been used as conventional biomarkers of exposure (Calsolaro et al. 198 
2017, Dziewirska et al. 2018, Hampl et al. 2016, Karwacka et al. 2019). However, since 1995 199 
(Sonnenschein et al. 1995) some authors proposed novel biomarkers of exposure to EDCs, 200 
which focus on detecting the biological effect of chemical compounds or metabolites, rather 201 
than detecting the presence of the EDC itself. In particular, the estrogenic activity of biological 202 
samples, measured with estrogenic activity assays, has been proposed and used as a novel 203 
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biomarker of exposure to EDCs. The main advantage of estrogenic activity assays is that they 204 
can assess the total effect induced by multiple, exogenous chemicals with estrogenic activity 205 
(xenoestrogens). Indeed, the chemical quantification of xenoestrogens provides an estimate of 206 
the real exposure. However, the cumulative estrogenic activity of a mixture is not the sum of 207 
the individual estrogenic activity of each xenoestrogen, since synergistic/antagonistic 208 
interactions must be taken into account. Moreover, the chemical analysis of xenoestrogens only 209 
takes into account specific known xenoestrogens and can not quantify the effect of unknown 210 
or unevaluated compounds (Bicchi et al. 2009, Escher et al. 2018, Jarošová et al. 2014, Kase 211 
et al. 2018, Könemann et al. 2018).  212 
Consequently, the use of estrogenic activity assays in human biological samples may have two 213 
main purposes, namely i) the assessment of total estrogenic effect to allow for the management 214 
of a wide range of physiological or clinical conditions in children as well as in adults, and ii) 215 
the improvement of the assessment of EDC exposure to allow for a better management of this 216 
important health and environmental issue.  217 
For the time being the development and application of estrogenic activity assays in human 218 
biological samples do not seem to be widespread, compared to other experimental tools.  219 
Nevertheless, their use could increase exponentially in the next years due to their versatility 220 
and holistic approaches. It is thus much needed to gain additional knowledge of their 221 
methodological approaches and applications relevant to them. 222 
The aim of the present review is to discuss the methodological approaches and the applications 223 
of estrogenic activity assays in human biological samples. A bibliographic research was 224 
performed: 75 research articles were analysed in order to summarize the methods used to treat 225 
biological samples and the results obtained.  226 
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The examined articles were divided into two categories, according to the use of estrogenic 227 
activity: i) to quantify the level of estrogens and/or as a biomarker of estrogenic status, ii) as a 228 
biomarker of exposure to EDCs. 229 
To quantify the level of estrogens and/or as a biomarker of estrogenic status, the estrogenic 230 
activity assays were applied in 38 of the analysed articles (table 1). Some authors mainly 231 
considered estrogenic activity assays as tools for the evaluation of estrogen levels, specifically 232 
for the evaluation of E2 levels (table 1, n° ref. 1- 8, 10-13, 18, 29, 32, 38). Other authors instead 233 
used these assays for their ability to measure the total estrogenic effect defined as “evaluation 234 
of estrogenic bioactivity” (table 1, n° ref. 9, 17). In this review, the application of estrogenic 235 
activity assays was intended as a tool to detect the total estrogenic effect, meaning that it was 236 
intended as a biomarker of “estrogenic status”, except for the articles published by Klein et al. 237 
where it was intended as a tool for estrogen quantification. In these 38 studies, serum and 238 
plasma were used as biological samples and they were analysed using gene reporter assays 239 
(using mammalian and yeast cells) and proliferation assays (E-screen assays). 240 
As biomarkers of exposure to EDCs, estrogenic activity assays were used in 37 of the analysed 241 
articles (table 2). In these studies, the biomarker was defined as “assessment of total estrogenic 242 
burden (TEXB)” (table 2, n° ref. 3), “total estrogenic xenobiotic burden” (table 2, n° ref. 4), 243 
“total effective xenoestrogen burden” (table 2, n° ref. 7, 15, 16, 21, 22, 35) or “xenoestrogenic 244 
activity” (table 2, n° ref. 11, 14, 32, 37). In this article the abbreviation “EDC biomarker” will 245 
be used. In these 37 studies, serum, adipose tissue, placenta and milk were used as biological 246 
samples and they were analysed using ligand-binding assays, gene reporter assays (using 247 






2. Assays for estrogenic activity evaluation  252 
Assays for estrogenic activity evaluation have been described in recent review articles (Mueller 253 
2004, Kiyama and Wada-Kiyama 2015, Wagner et al. 2017, Wangmo et al. 2018). For the 254 
assessment of the estrogenic activity in biological samples, three kinds of assays have been 255 
applied: ligand-binding assays, gene reporter assays and proliferation assays (E-screen assays). 256 
In the following sections the characteristics of these assays are briefly described considering 257 
their strengths/weaknesses (table 3) and their detection limits (table 4) in the assessment of 258 
estrogenic activity in biological samples. The assays validated by the Organisation for 259 
Economic Co-operation and Development (OECD) as tools to test potential EDC substances 260 
or by the International Organization for Standardization (ISO) as tools to assess water/waste 261 
water estrogenic activity are also listed. 262 
2.1. Ligand-binding assays 263 
Ligand-binding assays detect receptor–ligand interactions. These assays quantify the ability of 264 
a test chemical or a mixture to compete with E2 in binding to ER, and the result is often 265 
expressed as the concentration showing 50% displacement of E2 from receptor. The result can 266 
also be expressed as relative binding affinity with respect to E2 (Kiyama and Wada-Kiyama, 267 
2015). Ligand-binding assays were initially performed using radioactive ligands, while, more 268 
recently, assays using non-radioactive ligands have been developed. Ligand-binding assays are 269 
able to detect the binding to ER of both agonist and antagonist substances without 270 
distinguishing between the two effects (Seifert et al. 1999). This characteristic is an advantage. 271 
Indeed, while in other estrogenic activity assays agonist and antagonist effects could 272 
compensate each other resulting in a null activity, in ligand-binding assays this compensatory 273 
effect can not occur. However, the same characteristic can be a disadvantage, since these assays 274 
are unable to assess the total estrogenic effect induced by the interaction of agonist and 275 
antagonist substances (Mueller 2004).  276 
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To assess the estrogenic activity in biological samples, a ligand-binding assay has been applied: 277 
the enzyme linked receptor assay (Sapbamrer et al. 2010), a competitive enzyme immunoassay 278 
which uses non-radioactive ligands. Moreover, the OECD has validated two ligand-binding 279 
assays to screen and test potential EDC substances (OECD 2018), namely the Freyberger-280 
Wilson ER binding assay and the Chemical Evaluation and Research Institute (CERI) ER 281 
binding assay (OECD n° 493 2015).  282 
2.2. Gene reporter assays 283 
Gene reporter assays consist of the transfection of a reporter construct into mammalian or yeast 284 
cells. ER are transcription factors that induce the transcription of target genes after binding to 285 
specific DNA sequences in their promoter; the reporter construct is made of these DNA 286 
sequences linked to the gene of a measurable protein (for example the enzyme luciferase) 287 
(Sonneveld et al. 2005). Gene reporter assays are able to quantify the total estrogenic effect 288 
and are characterized by short incubation periods. However, the results of these assays can be 289 
ambiguous when substances with overactivation effects are included in the analysed sample. 290 
Gene reporter assays can be divided into two main categories. Some reporter gene assays are 291 
performed on cells that already express ERs, while others are performed on cells that do not 292 
express endogenous ERs. In the first category of gene reporter assays, cells are transfected with 293 
an estrogen-inducible reporter gene. These cells can be transiently or stably transfected, 294 
however, since stably transfected cells remain stable and ready for use, they are generally 295 
preferred (Soto et al. 2006, Wangmo et al. 2018). In the second category of gene reporter 296 
assays, cells are transfected with both an estrogen-inducible reporter gene and an ER 297 
expression construct. Since these cells do not express other ERs, the advantage of these assays 298 
is that they allow the evaluation of estrogenic activity in the samples distinguishing between 299 
ERα and ERβ estrogenic activity.  300 
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Numerous gene reporter assays have been applied for the assessment of estrogenic activity in 301 
biological samples. Moreover, two gene reported assays have been validated by the OECD to 302 
screen and test potential EDC substances (OECD 2018): the first uses ERα-HeLa-9903 cells 303 
and the second uses VM7Luc4E2 cells (OECD n° 455 2016). Both assays use human cells 304 
stably transfected with ERα, but the VM7Luc4E2 cells also express a minor amount of 305 
endogenous ERβ. As stated by the OECD, VM7Luc4E2 cells were originally designated as the 306 
BG1Luc cells, however, in-depth analyses revealed that these cells were not the BG1 cells, but 307 
instead a variant of the MCF-7 cells (OECD 2018). Recently, a gene reporter assay using stably 308 
transfected human cells has also been described in the ISO 19040-3 (ISO 2018) for the 309 
assessment of estrogenic activity in water and waste water. As for gene reported assays based 310 
on yeasts, two assays, based on Saccharomyces cerevisiae or Arxula adeninivorans, have been 311 
described in the ISO 19040-1 (2018) and in the ISO 19040-2 (2018) as methods for the 312 
assessment of estrogenic activity in water and waste water (Hettwer et al. 2018). 313 
2.3. Proliferation assays (E-screen assays) 314 
E-screen assays are proliferation tests. They measure the proliferative effect induced by 315 
estrogens or estrogenic substances on estrogen-responsive cells. Proliferation is determined 316 
through different procedures, including DNA staining and metabolic activity quantification. 317 
The first E-screen assay was developed by Soto et al. (1997) using human breast cancer cells 318 
(MCF-7), whose proliferation is mainly induced by the activation of ERα (Wagner et al. 2017). 319 
Later on E-screen assays were also applied using MCF-7 sublines, such as the MCF-7 BUS, in 320 
order to obtain a higher proliferative response (Martinez et al. 2016, Villalobos et al. 1995). 321 
Many E-screen assays have been applied for the assessment of estrogenic activity in biological 322 
samples, while they have not been reported by the OECD nor by the ISO (OECD 2018) to test 323 




3. Estrogenic activity as estrogen quantification and biomarker of estrogenic 326 
status: methodologies 327 
The research group of Klein was the first to developed an estrogenic activity assay in biological 328 
samples (table 1, n° ref. 1). They developed an estrogenic activity assay as estrogen 329 
quantification using yeasts (i.e. a strain of Saccaromyces cerevisiae) in which the detection 330 
limit was 0.02 pg/mL, in order to overcome the lack of sensitivity of available assays for E2. 331 
Klein et al. (1994) treated serum samples performing a liquid-liquid extraction with ether and 332 
demonstrated that this assay was highly specific for E2 with low cross-reactivity for estrogen 333 
metabolites and other hormones, suggesting that this high specificity could be due to many 334 
factors, including the extraction of the samples.  335 
The protocol of Klein et al. was mainly focused on measuring E2 and it was applied in many 336 
studies by the same research group (table 1, n°ref. 2-8, 10-13, 18, 22, 29, 32, 38). 337 
Other authors applied extraction to biological samples before the analysis: in the studies of 338 
Pedersen et al. (2010) and Chamas et al. (2017) samples were extracted using a liquid-liquid 339 
extraction with methyl tert-butyl ether and diethyl ether respectively, while in the study of 340 
Kanaya et al. (2015) samples were extracted using a solid-phase extraction.  341 
In 2002, the research group of Paris et al. developed an estrogenic activity assay for the 342 
determination of serum estrogenic activity using human uterine cervix carcinoma cells (HeLa) 343 
stably transfected with ERE-βGlob-Luc-SVNeo and pSG5ERαpuro or pSG5ERβpuro plasmids 344 
(HELNα or HELNβ, respectively). In contrast to Klein et al. (1994), Paris et al. (2002) tested 345 
serum samples without extraction and without any other sample treatment to keep their 346 
conditions closer to those of their physiological status, since their aim was to develop a protocol 347 
for the assessment of the total estrogenic activity rather than for E2 quantification. Their 348 
protocol, based on HeLa cells, was subsequently applied by several authors (table 1, n° ref. 15, 349 
17, 23, 24, 28) and it was also used by Séronie-Vivien et al. (2004) as a model to develop 350 
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another serum estrogenic activity assay based on breast cancer cells (MCF-7) stably transfected 351 
with ERE-βGlob-Luc-SVNeo plasmid (MELN). 352 
Other 11 articles reported in this review treated biological samples without any extraction (table 353 
1, n° ref. 16, 19, 20, 25, 26, 27, 30, 31, 34, 35, 37). In almost all protocols, samples were added 354 
to culture medium without any treatment. In four studies, however, samples were filtered (pore 355 
size 0.22 µm) before being added to culture medium (table 1, n° ref. 20, 25, 30, 32) and an 356 
aromatase inhibitor was added with a view to preventing the conversion of testosterone to E2 357 
by aromatase in the cells (table 1, n° ref. 20). Biological samples were tested in one or in 358 
different concentrations ranging from 1 to 20% in culture medium. 359 
The analysis of samples without extraction could be influenced by the complexity of 360 
serum/plasma samples, therefore some authors proposed different methodological approaches 361 
in order to consider the variability of these samples.  362 
The variability caused by serum components was considered by many authors in the 363 
construction of the standard curve. In five studies, the standard curve was produced for each 364 
sample and consisted of stripped serum from the same patient, to which incremental amounts 365 
of E2 were added (table 1, n° ref. 9, 15, 17, 23, 24, 28). Séronie-Vivien et al. (2004) considered 366 
this approach as essential when the assay was performed to quantify E2 in serum, because it 367 
was useful to remove the interference due to serum compounds different from E2, which 368 
modulate the estrogenic activity and differ from patient to patient. However, for the detection 369 
of estrogenic activity unrelated to E2 serum concentration, Séronie-Vivien et al. (2004) stated 370 
that a single standard curve could be performed using charcoal-stripped serum from a healthy 371 
volunteer in order to take into account a “normal overall estrogenic (transcriptional) activity of 372 
human serum”.  373 
Similarly to Séronie-Vivien et al. (2004), other authors used a single standard curve for all 374 
samples (table 1, n° ref. 19, 20, 25, 26, 27, 30, 31). The standard curve was generally 375 
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constructed by adding E2 to medium with charcoal-stripped serum/plasma at the same 376 
concentration as the sample’s one. For example, in the study of Lim et al. (2014a), samples 377 
were tested at a concentration of 10% in medium and the standard curve was constructed by 378 
adding E2 to 10% charcoal-stripped commercial human serum in medium. 379 
A similar approach was adopted by Sonneveld et al. (2005) in order to test different 380 
concentrations of serum samples (0-10%) avoiding the variability caused by serum 381 
components. For this purpose, the authors maintained the final serum concentration at 10% by 382 
supplementing lower percentages of the tested sera with charcoal-stripped bovine serum. 383 
Data were usually expressed as E2 equivalent quantity (EEQ), which is the total concentration 384 
of estrogenic active compounds normalised to the E2. However, Martínez et al. (2016) 385 
presented the results as estrogenic activity in comparison with a standard serum pool. In this 386 
study, each serum sample was tested with 0.5% serum pool, which was used as a reference 387 
standard to normalize the results. Other studies did not specify any peculiar approach to 388 
evaluate the results (table 1, n° ref. 35, 37). 389 
Like many hormones, estrogenic activity has a circadian rhythm, with nocturnal and early 390 
morning rises (Janfaza et al. 2006, Li et al. 2009). For this reason, some authors pointed out 391 
that they collected fasting blood samples during specific hours of the day, especially in the 392 
morning (table 1, n° ref. 3, 4, 5, 6, 7, 8, 10, 12, 13, 18, 21, 32, 34, 35, 38).  393 
 394 
4. Estrogenic activity as estrogen quantification and biomarker of estrogenic 395 
status: applications 396 
Estrogenic activity as estrogen quantification and biomarker of estrogenic status was applied: 397 
i) to detect physiological variations of estrogens, ii) to study pediatric diseases, iii) to analyse 398 
hormone-dependent diseases in women, iv) to evaluate estrogen suppression or enhancement 399 
after pharmaceutical treatments. 400 
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4.1. Physiological variations of estrogens  401 
Estrogenic activity assays were used to detect low concentrations of estrogens in children and 402 
in post-menopausal women, since the sensitivity of other assays for E2 quantification was too 403 
low.  404 
Klein et al. (1994) measured physiological estrogen levels using an estrogenic activity assay in 405 
prepubertal children, and found that the estrogen levels in prepubertal girls were higher than in 406 
prepubertal boys, suggesting that these hormones may contribute to higher rates of skeletal 407 
maturation, earlier puberty and earlier interruption of growth in girls compared to boys. The 408 
same results were obtained in the study of Paris et al. (2002) using a different assay for the 409 
evaluation of serum estrogenic activity. The role of estrogen levels in skeletal growth was 410 
confirmed in another study (Klein et al. 1996): estrogen levels measured in healthy growing 411 
boys were low throughout childhood, increased before puberty and rose steadily during 412 
adolescence. Moreover, there was a relationship between estrogen levels and testosterone 413 
concentrations and between estrogen levels and the time of peak growth velocity.  414 
The physiological variations of estrogens were further evaluated by Janfaza et al. (2006) in 800 415 
healthy children from birth to puberty. In the same study, the estrogen levels were measured 416 
every hour for 24 hours in 55 children. Estrogen levels: (i) increased with age and pubertal 417 
stage in both genders, (ii) showed a circadian rhythm with a nocturnal rise and (iii) were always 418 
higher in girls than in boys.  419 
The estrogenic activity/E2 level of prepubertal children was also evaluated to investigate the 420 
relationship between estrogenic activity and adiposity. The first study on this topic was 421 
performed by Klein et al. (1998b), whose results revealed that obese and nonobese children in 422 
prepubertal or early pubertal stage showed similar circadian rhythms and similar E2 levels. E2 423 
levels were not correlated with fat mass, body mass index, or arm fat, suggesting that E2 levels 424 
are not directly correlated with markers of adiposity. Similar results were obtained by Larmore 425 
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et al. (2002), who did not find a significant correlation between estrogen levels and body mass 426 
index or weight in their analysis of prepubertal and pubertal girls (obese and nonobese). 427 
Furthermore, the study of Mesa Valencia et al. (2019) did not show any association between 428 
estrogenic activity and markers of adiposity and metabolic and hormonal factors in prepubertal 429 
girls, suggesting that estrogenic activity is not influenced by adiposity. 430 
Estrogenic activity assays were also applied to detect low concentrations of 431 
estrogens/estrogenic compounds in postmenopausal women. Wang et al. (2005) applied a gene 432 
reporter assay using HeLa cells in samples of postmenopausal women, suggesting that such 433 
assays could be useful not only to determine the concentration of E2, but also to assess the total 434 
estrogenic activity. 435 
Indeed, the authors claimed that the assay was not completely specific for E2 but seemed to 436 
measure other biologically active estrogens as well. This hypothesis was supported by a 437 
subsequent study (Wang et al. 2013), in which another estrogenic activity assay was applied 438 
(E-screen assay). In this study, the serum estrogenic activity of postmenopausal women was 439 
strongly associated with serum E2 levels, but it was also positively or negatively associated 440 
with other serum molecules and women characteristics. These results suggested that the 441 
estrogenic activity is influenced not only by endogenous estrogen levels but also by other 442 
factors.  443 
Finally, the estrogenic activity was evaluated in mother-child pairs. The study of Pedersen et 444 
al. (2010) evaluated the estrogenic activity of both mother's and child's plasma (cord blood). 445 
The results showed that the estrogenic activity of cord blood plasma was higher than the one 446 
of mother plasma, and that the two parameters were loosely correlated. The authors also 447 
suggested that the high estrogenic activity of cord blood probably reflected the elevated 448 
estrogen production in the placenta and was not due to the presence of other estrogenic 449 
compounds such as EDCs. 450 
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4.2. Estrogenic activity and pediatric diseases 451 
Estrogenic activity assays were applied in order to analyse biological samples collected from 452 
children and adolescents with pediatric diseases characterized by hormonal dysregulation: 453 
precocious puberty, Turner’s syndrome, type 1 diabetes and sex differentiation disorders.  454 
4.2.1. Female precocious puberty 455 
Precocious puberty (PP) is defined as the appearance of secondary sex characteristics in girls 456 
aged under 8 years. PP is clinically distinguished between incomplete PP (premature thelarche, 457 
premature pubarche, isolated menarche) and true PP (complete or central PP) (Sultan et al. 458 
2018). Estrogenic activity assays have been used on both forms of PP by multiple studies. 459 
Three studies focused on incomplete PP and specifically on premature thelarche, which refers 460 
to the isolated breast development in girls aged under 8 without the development of any other 461 
sexual characteristics. The first study (Klein et al. 1999) performed on young girls (less than 3 462 
years of age) found that E2 levels in girls with premature thelarche were significantly higher 463 
than in normal prepubertal girls. In the second study (Paris et al. 2013) information on parental 464 
environmental/occupational exposure to EDCs during prenatal/postnatal patient life were 465 
collected through surveys, in addition to estrogenic activity evaluation. The estrogenic activity 466 
of girls with premature thelarche and whose parents had been exposed to EDCs was 467 
significantly higher compared to the one of healthy girls. Moreover, it was significantly higher 468 
compared to the estrogenic activity of girls with premature thelarche whose parents had not 469 
been exposed to EDCs. This suggested that some patients may be affected by this condition 470 
due to prenatal/postnatal EDC exposure. The third study (Pereira et al. 2015) investigated the 471 
relationship between estrogen levels and risk of premature thelarche, assessing the estrogen 472 
levels of prepubertal girls aged 7, who were monitored during the following years for the onset 473 
of thelarche. The results showed that girls with estrogen levels over 5 pg/ml at 7 years had an 474 
increased risk of presenting earlier thelarche onset. 475 
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E2 levels were evaluated using estrogenic activity assays also in girls affected by true PP. In 476 
the study of Larmore et al. (2002), average E2 levels were higher in pubertal girls than in 477 
prepubertal girls and in girls with PP. However, only E2 levels of normal pubertal and normal 478 
prepubertal girls were statistically different. A high estrogenic activity was also detected in a 479 
baby girl (4 months old) affected by precocious puberty (Gaspari et al. 2011b). Since high 480 
concentrations of pesticides were detected in the plasma of both the patient and her parents, as 481 
well as in the soil of their farm, the authors hypothesized a correlation between her precocious 482 
puberty and exposure to pesticides.   483 
4.2.2. Other female diseases  484 
Wilson et al. (2003) compared the serum E2 levels in prepubertal girls affected by Turner’s 485 
syndrome with healthy prepubertal girls, and found that girls with Turner’s syndrome had 486 
significantly lower E2 levels. Martínez et al. (2016) compared the serum estrogenic activity of 487 
post-menarcheal girls with type 1 diabetes to the estrogenic activity of normal post-menarcheal 488 
girls, finding a statistically significant difference in the estrogenic activity of girls with type 1 489 
diabetes compared to the control group. In these two studies, the application of estrogenic 490 
activity assay allowed to demonstrate that the lack of normal ovarian function in girls with 491 
Turner’s syndrome is evident even before puberty, and that type 1 diabetes can also affect 492 
estrogen metabolism. 493 
4.2.3. Sex differentiation disorders in males 494 
The study of Paris et al. (2006) found that the serum estrogenic activity of three children with 495 
male pseudo-hermaphroditism was higher than in controls. This result, coupled with the 496 
mother’s exposure to environmental EDCs during pregnancy, suggested that ambiguous 497 
genitalia could be related to foetal exposure to EDCs.  498 
Similarly, the study of Gaspari et al. (2011a) found that the serum estrogenic activity of young 499 
males with sex differentiation disorder was significantly higher in 11 males who had been 500 
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exposed to EDCs during the foetal period compared to 17 cases who had not been exposed and 501 
compared to controls. Also, the estrogenic activity of patients who had not been exposed to 502 
EDCs was not statistically different compared to controls, suggesting the possible relationship 503 
between EDC exposure and sex differentiation disorder of some males.  504 
4.3. Estrogenic activity and hormone-dependent diseases in women 505 
Many studies investigated the relationship between estrogenic activity and breast cancer.  506 
Séronie-Vivien et al. (2004) found that in controls the estrogenic activity was significantly 507 
correlated with serum E2 concentration, while in advanced breast cancer patients it was less 508 
correlated. In this study, the estrogenic activity was higher in controls than in patients, probably 509 
because many pre-menopausal women were included in the control group. 510 
Another study performed a similar comparison using a higher number of subjects 511 
(Widschwendter et al. 2009). In contrast with the previous study, the estrogenic activity, 512 
measured as estrogen receptor-α and estrogen receptor-β (ERα and ERβ) transcriptional 513 
activity, was higher in postmenopausal women with breast cancer compared to postmenopausal 514 
controls, although no difference was observed in serum E2 levels between the two groups. 515 
Moreover, this study suggested that estrogenic activity assays might predict ER-positive breast 516 
cancer at the time of the diagnosis, since women with estrogenic activity (ERα and ERβ) in the 517 
highest quintile among controls had 7.57- and 10.14-fold risk of general and ER-positive breast 518 
cancer respectively. 519 
Recently, Fourkala et al. (2012) performed a case-control study nested in a cohort study 520 
demonstrating that ERα transcriptional activity of serum collected more than two years before 521 
diagnosis was independently associated with breast cancer risk, while ERα activity, collected 522 
less than two years before diagnosis, and ERβ activity were not. The association between ERα 523 
transcriptional activity of serum, collected before diagnosis, and breast cancer risk was also 524 
confirmed by the analysis of Asian women in the study of Lim et al. (2014a). Women in the 525 
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highest quartile for ERα activity had an odds ratio of 2.39 compared with those in the lowest 526 
quartile. As reported also by Fourkala et al. (2012), cases and controls did not differ for ERβ 527 
transcriptional activity. 528 
Considering the results of these studies, estrogenic activity assays seem to be a useful tool to 529 
assess the risk assessment of breast cancer, since in most of the studies the serum estrogenic 530 
transcriptional activity was associated with breast cancer risk.  531 
Fejerman et al. (2016) measured the estrogenic activity of Latin-American women in order to 532 
understand whether estrogenic activity may be related to higher breast cancer risk in US-born 533 
Latinas compared to foreign-born. Using linear regression models, the authors found a positive 534 
association between estrogenic activity and years of US residence (considering foreign-born 535 
Latinas only), suggesting that the breast cancer risk observed in Latin-American women might 536 
be related to the estrogenic activity. 537 
Starting from this pilot study, Sanchez et al. (2019) assessed the association between estrogenic 538 
activity, demographic factors and breast cancer risk factors in American women of different 539 
racial/ethnic groups: Non-Latina Black, Non-Latina White and Latina women. Non-Latina 540 
Black women showed the highest estrogenic activity, followed by Non-Latina White women, 541 
while Latina women showed the lowest estrogenic activity. The multivariable analysis (which 542 
included several independent variables) showed that the difference between Non-Latina White 543 
and Latina women was statistically significant, as opposed to the difference between Non-544 
Latina Black and Non-Latina White women. The results of these two studies combined 545 
suggested that the use of estrogenic activity assays might also provide explanation regarding 546 
different breast cancer risk in different racial/ethnic groups living in the US.  547 
The estrogenic activity of serum was also evaluated in relation to another hormone-dependent 548 
disease in adults. Lim et al. (2012) considered the possible association between estrogenic 549 
activity (measured as ERα transcriptional activity) and hip fracture risk in postmenopausal 550 
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Asian women. A high serum estrogenic activity, evaluated before hip fracture, was associated 551 
with a reduced hip fracture risk. This reduction was still evident after adjustment for other 552 
known risk factors of hip fracture were made, including age and body mass index. The results 553 
suggested that a high estrogenic activity might prevent this hormone-dependent injury.  554 
Finally, the same authors evaluated the influence of serum estrogenic activity (measured as 555 
ERα and ERβ transcriptional activity) on lung cancer survival in postmenopausal Asian women 556 
(Lim et al. 2014b). Using regression analysis, they found that high ERβ transcriptional activity 557 
in sera was associated with a lower probability of lung cancer survival, while on the contrary 558 
estrogen levels and ERα transcriptional activity were not associated with the probability of 559 
survival. These results suggested that some serum activators of ERβ may lower the probability 560 
of lung cancer survival and that the evaluation of ERβ estrogenic activity in sera might serve 561 
as a prognostic marker to predict lung cancer survival. 562 
4.4. Estrogen suppression/enhancement after pharmaceutical treatments 563 
4.4.1. Females 564 
The suppression of E2 levels after pharmaceutical treatments was tested in girls affected by 565 
PP. In the study of Klein et al. (1998a), girls affected by PP were treated with different doses 566 
of deslorelin for 9 months and serum E2 levels were evaluated using estrogenic activity assay. 567 
The results showed that the suppression of E2 was dependent on the dose of deslorelin. 568 
However, E2 concentrations were always above the E2 levels of normal prepubertal girls 569 
regardless of the dose. 570 
Other authors evaluated E2 levels using estrogenic activity assays after pharmaceutical 571 
treatments in unhealthy girls. Taboada et al. (2011) assessed pharmacokinetics and 572 
pharmacodynamics of the same form of E2 administered orally and transdermally to girls with 573 
Turner’s syndrome. Girls were treated for two weeks with either a high or a low dose of E2 574 
administered orally or transdermally. This preliminary short-term study demonstrated that the 575 
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high dose of transdermal administration managed to restore the physiological levels of E2 and 576 
estrone, while oral administrations increased estrone concentration compared to both 577 
transdermal administration and controls regardless of the dose. High transdermal E2 578 
administration proved to be the most effective way to make the estrogenic activity of the 579 
patients the most similar to the estrogenic activity of controls.  580 
This preliminary short-term study was carried forward by the subsequent study of Torres-581 
Santiago et al. (2013). The authors assessed the metabolic effects and body composition 582 
changes in girls with Turner’s syndrome treated with the same form of E2 given orally or 583 
transdermally for a year. E2 doses were titrated in order to achieve E2 levels within the normal 584 
range of menstruating adolescents. The two treatments induced similar effects on numerous 585 
monitored parameters: follicle-stimulating hormone (FSH) and luteinizing hormone (LH) 586 
concentrations, body composition (weight, body mass index, percentage of fat mass, fat-free 587 
mass, abdominal fat), lipid concentrations and oxidation, resting energy expenditure rates and 588 
bone mineral density. However, since the estrogenic activity of serum samples, estrone and 589 
estrone sulfate concentrations were higher in girls treated orally with E2 than in girls treated 590 
with transdermal E2 administration, the authors concluded that transdermal administration 591 
might be more effective than oral administration in inducing a more physiological estrogenic 592 
status in girls with Turner’s syndrome. 593 
Estrogenic activity assays were also used to test women after pharmaceutical treatments. The 594 
first study to focus on women was the one of Klein et al. (1995), in which the E2 levels were 595 
measured using a bioassay in women affected by breast cancer and treated with different doses 596 
of an aromatase inhibitor for twelve weeks (100 µg/day - 5.0 mg/day of letrozole). The result 597 
of the study demonstrated that all doses of the drug induced an equivalent suppression of E2 598 
levels.  599 
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The second study on women tested the suppression and recovery of E2 after injection of a 600 
potent gonadotropin-releasing hormone receptor agonist (leuprolide acetate) in healthy 601 
volunteers (Larmore et al. 2000). Measured with an estrogenic activity assay, E2 levels were 602 
significantly suppressed by week 3 and further suppressed by week 4 after one injection of 603 
leuprolide acetate. E2 remained below postmenopausal levels for 5-8 weeks after one injection 604 
and for 6 weeks after a second injection (4 weeks apart).  605 
Finally, Santen et al. (2002) investigated the estrogenic activity of serum collected from 606 
postmenopausal women affected by urogenital atrophy and treated with vaginal E2, in order to 607 
determine the lowest dosage needed to reverse signs and symptoms of urogenital atrophy 608 
without substantially increasing serum E2 levels. As measured by bioassay, a dose equal to 10 609 
µg of vaginal E2 relieves the symptoms of urogenital atrophy and induces objective vaginal 610 
changes without increasing serum E2 levels. 611 
4.4.2. Males 612 
E2 suppression can be induced in boys with severe growth retardation in order to delay puberty 613 
and then the epiphyseal fusion, thus maximizing height potential. For this purpose, Mauras et 614 
al. (2000) analysed the performance of anastrozole, a nonsteroidal aromatase inhibitor that 615 
blocks the conversion of Δ4-androstenedione to estrone and of testosterone to E2. The drug 616 
was tested in healthy young boys and the results showed that E2 concentrations were 617 
dramatically reduced after anastrozole administration. The drug seemed to be well tolerated 618 
and safe, since the treatment did not affect body composition, protein kinetics/substrate 619 
oxidation rates, muscle strength, and bone calcium metabolism. Based on these results, the 620 
authors stated that anastrozole appears to be suitable to treat boys with growth retardation.  621 
This hypothesis was further supported by the same authors in a subsequent study (Mauras et 622 
al. 2004). In this study, growth hormone (GH) deficient boys were treated for 12 months with 623 
GH (control group) or with GH and anastrozole in order to suppress estrogen production and 624 
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delay epiphyseal fusion. After the treatment, E2 concentrations decreased in boys treated with 625 
anastrozole and increased in the control group. Testosterone levels were higher in boys treated 626 
with anastrozole compared to control group. Although both treatments did not increase 627 
predicted adult height, anastrozole treatment dramatically decreased estrogen concentrations 628 
without effects on body composition, plasma lipids, and bone metabolism. 629 
Estrogenic activity assays were also used to assess the effect of the decoction of a Chinese 630 
medicinal plant (Epimedium pubescens), compared to the effect of a standard estrogenic 631 
prodrug (estradiol valerate) generally used to counteract menopausal symptoms (Li et al. 2009). 632 
The study was performed on male subjects in order to reduce the interference due to 633 
endogenous estrogens, and the estrogenic activity was evaluated in serum using different assays 634 
(ERα and ERβ gene reporter assays and E-screen assay). Ingestion of the standard drug induced 635 
a significant increase of serum estrogenic activity using all assays, while the plant decoction 636 
only induced a small but significant increase of ERα transcriptional activity, suggesting that 637 
the administration of this traditional decoction may not be suitable to counteract menopausal 638 
symptoms. 639 
 640 
5. Estrogenic activity as a EDC biomarker: methodologies 641 
Human biological samples can contain endogenous steroidal estrogens, but also EDCs with 642 
estrogenic activity called xenoestrogens, which can be introduced in the human body through 643 
inhalation, ingestion of contaminated food/water, and dermal contact. Since the evaluation of 644 
estrogenic activity through assays measures the effect induced by all estrogenic compounds, 645 
the use of these methods alone is unable to determine whether a phenomenon is induced by 646 
endogenous estrogens or xenoestrogens. Therefore, in order to use estrogenic activity assays 647 
as a EDC biomarker, in most studies the biological samples were treated in order to remove 648 
endogenous estrogens.  649 
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The studies of Sonnenschein et al. (1995) and Soto et al. (1997) are to our knowledge the first 650 
ones that applied estrogenic activity assays as a biomarker. The protocol follows multiple 651 
stages: (i) serum sample extraction, (ii) acid cleanup and (iii) separation of xenoestrogens from 652 
endogenous estrogens by high-performance liquid chromatography (HPLC) in silica column 653 
using the method proposed by Mendina and Sherman (1986). The separation is based on the 654 
elution time from the HPLC column. Since xenoestrogens (estrogenic pesticides, PCBs, 655 
hydroxylated PCBs, phenolic antioxidants and plasticizers) and endogenous estrogens have 656 
different elution times, xenoestrogens can be collected during the first 10 minutes of elution. 657 
However, some xenoestrogens, such as phytoestrogens, diethylstilbestrol and mycoestrogens 658 
cannot be extracted through this technique, as their retention time is longer than 12 minutes 659 
(Soto et al. 1997).  660 
The protocol proposed by Sonnenschein et al. (1995) and optimized by Soto et al. (1997) was 661 
further refined and modified by Rasmussen et al. (2003) by the introduction of solid-phase 662 
extraction and a modified HPLC gradient, with elution of xenoestrogens within 5.5 minutes. 663 
Rasmussen et al. (2003), who analysed serum samples from pregnant women, stated that two 664 
subfractions of the extract collected during the first 5.5 minutes could contain pregnancy-665 
related hormones (5α- dihydroprogesterone and fatty acid esters of estrone or E2). These 666 
subfractions (1.8 – 2.3 min and 3.8 – 4.3 min) were thus removed for the sake of analysis. In a 667 
subsequent study, Andersen et al. (2007) collected the xenoestrogens during the first 8 minutes 668 
in order to include more hydrophilic pesticides. However, they removed an additional 669 
subfraction (6.2–7.1 min) to avoid pregnenolone. The protocol, improved by Rasmussen et al. 670 
(2003), was applied in eight other studies (table 2, n° ref. 10, 11, 12, 13, 14, 19, 20, 27).  671 
Starting from this protocol, which was focused mainly on the extraction of persistent EDCs, 672 
Bjerregaard-Olesen et al. (2015) developed an extraction method for serum samples which was 673 
optimized for perfluorinated alkyl acids (PFAA). As the previous one, this method is composed 674 
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by solid-phase extraction (water phase), liquid/liquid extraction (tetrahydrofuran/n-hexane) 675 
and HPLC fractionation (extract collected between 22.01 and 26.00 min). However, since after 676 
the HPLC fractionation estriol and estetrol are still present, this method also contains a weak 677 
anion exchange extraction in order to remove these endogenous hormones from the final 678 
extract. This protocol optimized for PFAA was subsequently applied in three studies (table 2, 679 
n° ref. 33, 36, 37). 680 
Recently, a third protocol with HPLC fractionation was developed in order to analyse human 681 
serum samples (Pastor-Barriuso et al. 2016). In this protocol, the HPLC fractionation is 682 
preceded by liquid-liquid and solid-phase extractions. 683 
In 1997, the Spanish research group of Rivas and Olea (1997) published another methodology 684 
to assess the estrogenic activity as a EDC exposure biomarker using adipose tissue samples 685 
instead of serum samples. The authors proposed a protocol in which the adipose tissue was 686 
dissolved in hexane and eluted with hexane in a glass column filled with Alumina Merck 90; 687 
the eluate obtained was then concentrated and injected in HPLC for separation of 688 
xenoestrogens from endogenous estrogens. The HPLC fractionation was performed using the 689 
method previously proposed for serum samples (Sonnenschein et al. 1995). Three fractions 690 
from HPLC were collected: α-fraction, during the first 11 minutes, containing xenoestrogens; 691 
x-fraction from 11 to 13 minutes; β-fraction from 13 to 25 minutes containing endogenous 692 
hormones. However, since additives and monomers from plastics (such as bisphenols) are 693 
collected alongside endogenous hormones, their effect can not be evaluated analysing the 694 
fraction of xenoestrogens. 695 
This HPLC separation protocol was applied by some authors on human adipose tissues (table 696 
2, n° ref. 4, 7, 8, 15, 16, 21, 26, 35), while others applied it on human placentas (table 2, n° ref. 697 
16, 17, 22, 23, 25, 30, 31). 698 
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In contrast to previously reported studies, which used extraction and HPLC fractionation, two 699 
articles (Natarajan et al. 2002, Sapbamer et al. 2010) separated endogenous estrogens by 700 
xenoestrogens with two alternative methods. The former used polyclonal antibodies to 701 
immunoprecipitate the endogenous estrogens (E2) and then separate them from the 702 
xenoestrogens. In the latter dextran-coated charcoal (DCC) was used to remove all gonadal 703 
hormones. The DCC is made from acid washed charcoal powder and dextran and it is generally 704 
used to reduce the levels of estrogens in foetal bovine serum, producing the dextran coated-705 
charcoal stripped serum. However, it is important to bear in mind that, as reported by the 706 
manufacturer’s instructions (Sigma Product Information), although this treatment may reduce 707 
the levels of estrogens in the sample it might not completely eliminate estrogens or any other 708 
steroids from the serum.  709 
Other studies did not apply any separation technique but extracted the biological sample and 710 
tested the whole extract. In the study of Plíšková et al. (2005), half of a crude extract was used 711 
for the determination of overall estrogenic activity, while the other half was placed on a sulfuric 712 
acid-activated silica column, eluted with n-hexane: diethyl ether mixture, evaporated, and 713 
redissolved in DMSO, in order to elute only persistent compounds (including PCBs, 714 
polychlorinated dibenzo-p-dioxins and dibenzofurans). 715 
In the studies of Arrebola et al. (2012, 2013), an evaluation without separation was performed 716 
in order to assess the combined effect of endogenous estrogens and xenoestrogens, since the 717 
estrogenic activity of the whole extract can be considered as a measure of the effect of complex 718 
interactions among all estrogenic compounds (i.e. xenoestrogens and endogenous hormones). 719 
However, the estrogenic effect of endogenous hormones may be underestimated using this 720 
approach. Indeed, as specified by the same research group (Fernández et al. 2007a), this 721 
protocol was developed to efficiently extract lipophilic xenoestrogens and, as such, it may not 722 
be so effective to extract endogenous hormones. Nonylphenol, octylphenol and BPA, the most 723 
30 
 
polar xenoestrogens, may also be inefficiently extracted by increasing the under-estimation of 724 
the interaction among estrogenic compounds within the sample (Fernández et al. 2007a). 725 
Finally, some studies did not apply any separation techniques and did not extract biological 726 
samples but tested them without any treatment as a EDC biomarker (Brouwers et al. 2011, 727 
Kanno et al. 2007). 728 
 729 
6. Estrogenic activity as a EDC biomarker: applications 730 
The evaluation of estrogenic activity as a EDC biomarker might be a useful tool to understand 731 
the relationship between emission, exposure, biological effects and health risks associated with 732 
EDCs.  733 
This evaluation can be used for EDC exposure assessment (Andersen et al. 2007) and it can be 734 
considered as a biomarker of biological effective dose (Sonnenschein et al. 1995, Soto et al. 735 
1997). However, some authors seem to apply the biomarker also as a biomarker of effect 736 
(Bonefeld-Jørgensen 2014), as it can measure the effects induced on the organism by multiple 737 
chemicals considering all the possible interactions among them.  738 
6.1. EDC biomarker and exposure to pesticides, polychlorinated biphenyls and 739 
perfluorinated alkylacids 740 
Rivas et al. (2001) evaluated the estrogenic activity of adipose tissue extracts containing 741 
xenoestrogens (HPLC fractionation technique) collected in 400 women as a EDC biomarker. 742 
The concentrations of 16 organochlorine pesticides were also quantified in the extracts, but the 743 
concentration of each pesticide was not correlated with the EDC biomarker. The authors 744 
claimed that this finding could be due to the combined effect of pesticides and/or to the effect 745 
of substances that had not been measured. A subsequent study of Fernández et al. (2004) 746 
confirmed that the combined effect of compounds is difficult to predict considering the effect 747 
of each one: the authors found that the estrogenic activity of a serum extract (consisting of 748 
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different extract fractions obtained with HPLC fractionation technique) rarely corresponded to 749 
the sum of the estrogenic activity of each fractions.  750 
In contrast with the results of Rivas et al. (2001), in the study of Andersen et al. (2007) the 751 
estrogenic activity of serum extracts containing xenoestrogens (HPLC fractionation technique) 752 
was significantly and positively associated with pesticide exposure evaluated through 753 
interviews both with pregnant and non-pregnant women working in Danish greenhouses. The 754 
results of this study also demonstrated that the EDC biomarker is representative of recent 755 
exposures. Indeed, among pregnant women, the positive association was only significant for 756 
those who had been working one week before the sampling, while no association was observed 757 
for women working in the previous period. 758 
A negative association between PCB exposure and estrogenic activity was observed by 759 
Plíšková et al. (2005) who studied men living in a PCB polluted area and in a control 760 
background area (different districts in eastern Slovakia). Serum extracts containing persistent 761 
compounds (extraction technique optimized for persistent compounds) from people living in 762 
the background area showed higher estrogenic activity, while extracts from the polluted area 763 
showed an antiestrogenic activity. The association between PCB exposure and antiestrogenic 764 
activity was also confirmed by the comparison between the total estrogenic activity and PCB 765 
concentrations, since the estrogenic activity of the extracts containing endogenous estrogens 766 
and persistent compounds (crude extracts) was lower in the samples with high PCB levels. 767 
Since the levels of E2 decreased in the samples with high PCB levels, the authors stated that 768 
exposure to high PCB levels might also affect concentration of E2 in blood, causing the 769 
decrease of estrogenic activity and an overall antiestrogenic effect.  770 
Kanno et al. (2007) studied the estrogenic activity of serum samples (without treatment) 771 
collected from patients who underwent hemodialysis and peritoneal dialysis compared to a 772 
control group. The patients’ sera had higher levels of BPA compared to controls and they 773 
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induced a higher estrogenic activity compared to the activity expected for the measured BPA 774 
levels. The authors discussed the results, claiming that the high level of BPA was probably due 775 
to the release of BPA from the dialyzers to patient’s serum and that the unexpectedly high 776 
estrogenic activity could be due to the release of other EDCs, such as phthalate diesters in 777 
patient’s serum. 778 
Brouwers et al. (2011) studied men with different EDC exposure levels and found that 779 
occupational exposure to pesticides, disinfectants and exhaust fumes were associated with 780 
increased plasma estrogenic activity (without treatment). Instead, body mass index, use of 781 
personal care products and proximity to city centre were not associated with the EDC 782 
biomarker. 783 
However, the results of Kanno et al. (2007) and Brouwers et al. (2011) could have been 784 
influenced by a possible interference of xenobiotics with endogenous estrogen levels, since the 785 
authors used the estrogenic activity in total plasma/serum as a EDC biomarker without dividing 786 
endogenous estrogens from xenoestrogens.  787 
Finally, Bjerregaard-Olesen et al. (2016) studied the relationship between exposure to PFAAs 788 
and estrogenic activity of serum extracts containing PFAAs (HPLC fractionation technique) in 789 
pregnant women.  Their study found positive linear associations between the estrogenic activity 790 
and the PFAA serum levels but also inverse linear associations between extracts with an 791 
antiestrogenic activity (when tested with E2) and PFAA serum levels.  792 
6.2. EDC exposed populations 793 
The EDC biomarker was used to study Nordic populations, which are considered to be highly 794 
exposed to persistent organic pollutants (POPs) and EDCs, since numerous POPs (such as 795 
PCBs, dioxins and organochlorine pesticides) are also classified as EDCs. Due to their 796 
resistance to environmental degradation, POPs are transported to the Arctic by the atmosphere 797 
and ocean currents; here, due to their chemical characteristics, they are bioaccumulated in the 798 
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adipose tissue of animals and then of humans through their diet. Nordic populations are 799 
particularly exposed to POPs since their diet consists of a high intake of fish and marine animals 800 
(seals, whales, polar bears, seabirds) and includes the consumption of tissues and organs that 801 
contain animal fats where POPs are highly accumulated (liver, blubber, skin) (Bonefeld-802 
Jørgensen et al. 2010).  803 
Rasmussen et al. (2003) studied the estrogenic activity of serum extracts containing 804 
xenoestrogens (HPLC fractionation technique) collected from three groups of women: 30 805 
pregnant Danish women (slightly exposed), 60 non-pregnant Danish women (slightly exposed) 806 
and 211 pregnant Faroese women (highly exposed through diet), and found that the EDC 807 
biomarker was higher in Faroese women compared to Danish women. 808 
Other authors studied the Inuit Greenlandic populations as exposed populations, and compared 809 
the Inuit men with European men from Sweden, Poland (Warsaw) and Ukraine (Kharkiv). The 810 
results of the comparison showed that Inuit serum extracts containing xenoestrogens (HPLC 811 
fractionation technique) induced no estrogenic activity but elicited an antagonistic effect when 812 
the extracts were tested in combination with E2 (71% of samples) (Bonefeld-Jørgensen et al. 813 
2006). Contrarily, some European extracts induced estrogenic activity and only a few extracts 814 
elicited an antagonistic effect when tested with E2 (7-30% of samples). The EDC biomarker 815 
was not strongly associated with serum concentration of POPs (Bonefeld-Jørgensen et al. 2006) 816 
and no consistent association was found between the EDC biomarker and the adult semen 817 
quality assessed as sperm concentration, motility and morphology (Toft et al. 2007). In addition 818 
to lower estrogenic activity, Inuits were found to have lower sperm DNA damage, while in 819 
Europeans the estrogenic activity was positively correlated with DNA damage, suggesting that 820 
altered estrogenic activity together with genetic and/or nutrient factors may protect Inuits' 821 
sperm DNA from damage (Long et al. 2007). Different correlations between sperm DNA 822 
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damage and the EDC biomarker were further showed when comparing Inuits and Europeans 823 
using another assay (sperm chromatine structure assay) (Krüger et al. 2008b).  824 
The EDC biomarker was also used to study differences among Inuit populations across 825 
Greenland. The study of Krüger et al. (2008a) measured the estrogenic activity of serum 826 
extracts (HPLC fractionation) in men and women from different Greenlandic districts (Nuuk, 827 
Sisimiut and Qaanaaq) to evaluate associations between the EDC biomarker, POPs 828 
concentrations (14 PCBs and 10 pesticides), and lifestyle characteristics. The EDC biomarker 829 
showed different levels depending on districts and genders. In accordance with previous 830 
studies, male and female serum extracts generally induced a decrease in estrogenic activity and 831 
showed an antagonistic effect when the extracts were tested in combination with E2. Overall, 832 
few correlations were observed between the EDC biomarker and concentrations of each PCB 833 
and pesticide. A similar experimental study was performed in 2012 by the same authors 834 
(Krüger et al. 2012) in other Greenlandic districts (Ittoqqortoormiit, Narsaq and Qeqertarsuaq). 835 
The levels of the EDC biomarker were different depending on the district. The Ittoqqortoormiit 836 
serum extracts contained high levels of POPs and elicited an antagonistic effect similar to the 837 
extracts tested in the previous study (Nuuk, Sisimiut and Qaanaaq). On the contrary, a higher 838 
agonistic effect was observed in Qeqertarsuaq and Narsaq extracts. As summarized by two 839 
reviews (Bonefeld-Jørgensen 2010, Bonefeld-Jørgensen et al. 2014), the results of studies on 840 
Greenlandic Inuit suggested that the EDC biomarker is negatively correlated with POPs and it 841 
can be used as a biomarker in order to detect POP exposure.  842 
6.3. EDC exposure and adult adverse health effects 843 
The EDC biomarker was also applied to study the association with type 2 diabetes and breast 844 
cancer. 845 
Arrebola et al. (2013) applied the estrogenic activity measured in adipose tissues (extraction 846 
technique) of adults from Southern Spain as pesticide and PCB exposure biomarker, in order 847 
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to evaluate the possible role of these substances for the onset of type 2 diabetes. In the study, 848 
the concentrations of pesticides and PCBs in adipose tissue and serum were associated with 849 
type 2 diabetes, while the EDC biomarker was not associated with the disease and did not 850 
influence the effect of the substances on the disease, indicating that estrogenic activity may not 851 
be a critical factor for the onset of diabetes.  852 
Among the studies on breast cancer, Ibarluzea et al. (2004) evaluated the estrogenic activity of 853 
two types of adipose tissue extracts (containing xenoestrogens and containing endogenous 854 
estrogens- HPLC fractionation technique) and the concentration of 16 organochlorine 855 
pesticides in the adipose tissue in a case-control study, comparing women who had just been 856 
diagnosed with cancer and control women. No significant differences were observed in 857 
concentrations of pesticides and in the estrogenic activity of extracts containing xenoestrogens 858 
between the two groups. However, in women with a body mass index below the median 859 
(especially for the postmenopausal group), the high estrogenic activity of extracts containing 860 
xenoestrogens was associated with increased risk of breast cancer. The association was 861 
detected only by considering the activity of extracts containing xenoestrogens, while no 862 
association was found between breast cancer risk and the estrogenic activity of extracts 863 
containing endogenous estrogens (Fernández et al. 2007b). This first evidence of a significant 864 
association between the EDC biomarker and the risk of breast cancer was further investigated 865 
considering potential confounders and covariates (Fernández et al. 2007a). In patients, the 866 
estrogenic activity of adipose tissue extracts containing xenoestrogens (EDC biomarker) 867 
(HPLC fractionation technique) was associated with age, family history of breast cancer, 868 
lactation experience and smoking, while in controls it was only associated with age. Moreover, 869 
in patients the estrogenic activity of adipose tissue extracts containing endogenous estrogens 870 
(HPLC fractionation technique) was associated with age, educational level, age at menarche, 871 
menopausal status, marital status, lactation experience and smoking, while in controls it was 872 
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only associated with menopausal status. Therefore, the analysis of confounders and covariates 873 
showed that the EDC biomarker might also be sensitive to environmental, dietary, lifestyle, 874 
genetic and reproductive factors. 875 
A similar case-control study (Pastor-Barriuso et al. 2016) investigated the relationship between 876 
the EDC biomarker and breast cancer risk using serum instead of adipose tissue samples. No 877 
significant difference was observed in concentrations of each organohalogenated compound 878 
(PCBs, hexachlorobenzene, p,p’-dichlorodiphenyldichloroethylene) between women with 879 
breast cancer and controls. In contrast with the previous study, the estrogenic activity of both 880 
types of extracts (containing xenoestrogens and containing endogenous estrogens -HPLC 881 
fractionation technique) was higher in cases than in controls and the estrogenic activity 882 
measured in serum extracts was not associated with potential confounders (e.g. age, body mass 883 
index) except for geographical region. Nevertheless, in accordance with the previous study, 884 
this study highlighted the importance of the EDC biomarker since it demonstrated a strong 885 
positive association between the estrogenic activity of extracts containing xenoestrogens and 886 
the risk of breast cancer. Moreover, it revealed an association with a sigmoidal trend between 887 
estrogenic activity of extracts containing endogenous estrogens and breast cancer risk. 888 
A perspective study was conducted by the same research group in order to evaluate the effect 889 
of breast cancer treatment (chemotherapy and/or radiotherapy) and the influence of cancer 890 
progression on the EDC biomarker (Fernández et al. 2017). The authors assessed the estrogenic 891 
activity of adipose tissue in breast cancer patients at the diagnosis and during four other 892 
consecutive periods (<6, 6-12, 12-18, >18 months) and found that estrogenic activity of both 893 
types of extracts (containing xenoestrogens and containing endogenous estrogens -HPLC 894 
fractionation technique) increased during the treatment with a maximum peak  reached at 6-12 895 
months, suggesting that cancer treatment might influence the levels of the EDC biomarker. 896 
37 
 
These studies demonstrated the association of the EDC biomarker with the risk and progression 897 
of breast cancer in Spanish women. Nevertheless, the same results were not obtained in a 898 
similar study performed on serum samples of Inuit women (Wielsøe et al. 2018). Indeed, in 899 
this case-control study, the authors evaluated the estrogenic activity of two types of serum 900 
extracts containing lipophilic xenoestrogens and containing PFAAs (HPLC fractionation 901 
technique); the results showed that the estrogenic activity of both extracts was not associated 902 
with breast cancer risk. This unexpected result can be due to the different assays used for the 903 
assessment of estrogenic activity. Indeed, this study applied a gene reporter assay, while the 904 
previous studies evaluated the estrogenic activity through the E-screen assay which is a 905 
proliferation assay. Moreover, other differences might be responsible for the discrepancy 906 
among the results, namely different characteristics among the studied populations, extraction 907 
methods and exposure levels. 908 
6.4. Mother EDC exposure and child adverse health effects 909 
Since exposure to EDCs during pregnancy could represent a risk for children, some authors 910 
applied the EDC biomarker in order to detect a possible association between the estrogenic 911 
activity of placenta/serum extracts collected in mothers and adverse health effects in their 912 
children. 913 
To our knowledge, Fernández et al. (2007c) is the first study in which the EDC biomarker was 914 
applied for this purpose. The aim of this study was to investigate the mother-child exposure to 915 
organochlorine chemicals and its association with the risk of male urogenital malformations. 916 
The estrogenic activity was evaluated on placenta samples collected from mothers whose 917 
children were affected by cryptorchidism and/or hypospadias (n=46) and from controls. The 918 
estrogenic activity of two types of extracts (containing endogenous estrogens and containing 919 
xenoestrogens- HPLC fractionation technique), was not associated with the concentration of 920 
16 organochlorine pesticides measured in the extracts. However, the estrogenic activity of 921 
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extracts containing xenoestrogens (EDC biomarker) showed a weak association with the risk 922 
of malformation, which was stronger when adjusted for maternal age and birth weight. The 923 
results of the study suggested that the EDC biomarker may be a risk factor for cryptorchidism 924 
(Fernández et al. 2007b). 925 
Other studies evaluated the effects on children of exposure to xenoestrogens during pregnancy. 926 
In the study of Vilahur et al. (2013), the estrogenic activity of placenta extracts containing 927 
xenoestrogens (HPLC fractionation technique) was positively associated with increased birth 928 
weight and with a decrease in the risk of a rapid growth only in boys, although no association 929 
was found between the EDC biomarker and body mass index measured at 14 months of age. 930 
These results suggested that exposure to xenoestrogens during pregnancy may affect male child 931 
health in particular. A sex difference was also observed in two subsequent studies of the same 932 
authors (Vilahur et al. 2014a, Vilahur et al. 2014b). The first study showed an association 933 
between increasing levels of estrogenic activity in extracts containing xenoestrogens (HPLC 934 
fractionation technique) and lower AluYb8 DNA methylation, both measured in placentas of 935 
male children, while no significant effect was detected analysing placentas of female children. 936 
In the second study (Vilahur et al. 2014b), a lower average on motor development tests at 1-2 937 
years of age was observed in boys with mothers having high estrogenic activity of placentas 938 
(extracts containing xenoestrogens- HPLC fractionation technique), while no associations were 939 
observed in girls. The association was not found in children at 4-5 years and neither in the 940 
analysis of mental and cognitive tests in children at 1-2 years and 4-5 years. 941 
Recently, Bjerregaard-Olesen et al. (2019) investigated the associations between exposure to 942 
xenoestrogens during pregnancy (evaluated with the EDC biomarker) and child parameters (i.e. 943 
birth weight, length and head circumference). Differently from the other studies, in this study 944 
the biomarker was evaluated not in placenta extracts but in serum extracts and an extraction 945 
optimized for PFAAs was used (HPLC fractionation technique and PFAA extraction). The 946 
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results showed that a higher estrogenic activity of serum extracts containing PFAAs was 947 
associated with lower birth weight and length of children, suggesting that PFAA exposure 948 
during pregnancy may affect child growth. 949 
Finally, since EDC exposure during the first life period of children can occur through milk, 950 
Sapbamrer et al. (2010) studied the relationship between maternal estrogenic activity of serum 951 
and activity of breast milk (both treated in order to remove endogenous estrogens-DCC 952 
technique) and the correlation between estrogenic activity and lipid levels. The results showed 953 
a correlation between serum estrogenic activity and serum lipid levels, while no correlation 954 
was found in milk. Moreover, the study demonstrated that the estrogenic activity in breast milk 955 
was 8–13.5 times higher than in serum and that the two EDC biomarkers were not significantly 956 
correlated, suggesting that child exposure through milk can not be precisely estimated 957 
analysing maternal serum.  958 
 959 
7. Conclusion 960 
Estrogenic activity assays in human biological samples were applied for two main purposes: 961 
i) as estrogen quantification and/or biomarker of estrogenic status;  962 
ii) as a biomarker of exposure to EDCs. 963 
Different methodologies were applied for the first purpose: some authors extracted biological 964 
samples, while others tested them directly without any treatment. Several methodologies were 965 
applied in order to obtain different levels of specificity: highly specific protocols with 966 
extraction allowed the quantification of low concentrations of E2, while less specific protocols 967 
without extraction, allowed the quantification of the total estrogenic activity. 968 
Estrogenic activity as estrogen quantification and biomarker of estrogenic status was useful to 969 
detect low concentrations of estrogens/estrogenic compounds and allowed the detection of 970 
physiological variations of these compounds in prepubertal children and postmenopausal 971 
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women. This biomarker was also useful to study pediatric diseases characterized by hormonal 972 
dysregulation and women hormone-dependent diseases. Overall, in many studies a high 973 
estrogenic activity was associated with PP in females and sex differentiation disorders in males 974 
and in some studies the use of this biomarker allowed the identification of EDC exposure as a 975 
possible risk factor for these two diseases. Moreover, in girls the biomarker was also associated 976 
with Turner syndrome (one study) and type 1 diabetes (one study), while in women a high 977 
estrogenic activity was associated with higher breast cancer risk (three studies), lower hip 978 
fracture risk (one study) and lower lung cancer survival (one study). These relationships should 979 
be evaluated with caution since they were only demonstrated in a limited number of studies 980 
and through the analysis of small groups of subjects. Furthermore, the results may have been 981 
influenced by the type of estrogenic activity assay applied: some correlations were statistically 982 
significant mainly using a type of estrogenic activity assay (e.g. ERα transcriptional activity 983 
was correlated with breast cancer in all studies, while ERβ was correlated only in one out of 984 
three studies; ERβ transcriptional activity was correlated with lower probability of lung cancer 985 
survival, while ERα transcriptional activity was not). This biomarker was also important to 986 
monitor estrogen suppression/enhancement in females and males treated with different drugs: 987 
deslorelin, oral E2, transdermal E2, vaginal E2, letrozole, leuprolide acetate, anastrozole, 988 
decoction of a Chinese medicinal plant. 989 
For the second purpose, in order to use estrogenic activity assays as a EDC biomarker different 990 
methodologies were applied on biological samples: some authors extracted biological samples, 991 
while others tested them directly without any treatment; some authors divided endogenous 992 
estrogens from xenoestrogens, while others tested samples without separation. The analysis of 993 
these methodologies outlined some limitations. Regardless of the technique used for extraction 994 
(solid phase extraction, liquid/liquid extraction or both) and separation (HPLC, 995 
immunoprecipitation, DCC), the extraction collects different compounds with different 996 
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efficiencies depending on the protocol. Thus it may underestimate the effect of some 997 
compounds, while the separation using HPLC is not always able to divide endogenous 998 
hormones from xenoestrogens correctly.  999 
Since the EDC biomarker might be a useful tool to understand the relationship between 1000 
exposure, biological effects and health risks associated with EDCs, it was used: (i) to study its 1001 
relationship with exposure to EDCs, (ii) to investigate its relationship with adverse health 1002 
effects, and (iii) to compare exposed populations with not exposed populations. The EDC 1003 
biomarker showed different associations with exposure to different EDCs. This result can be 1004 
explained considering that different EDCs may induce different estrogenic effects (agonistic 1005 
or antagonistic effects), and that the EDC biomarker quantifies the cumulative effect induced 1006 
by the combination of all these effects. Moreover, this result may also be due to different 1007 
methodologies applied in different studies (extraction/no extraction and separation/no 1008 
separation). Indeed, when samples were tested without separation the EDC biomarker also 1009 
quantified the interaction between EDCs and endogenous hormones, while, when samples were 1010 
tested after separation, this interaction was not measured. Conflicting results were also found 1011 
analysing exposed populations (i.e. antagonistic effect measured in most of the Inuit 1012 
populations, estrogenic activity measured in Faroese women), these results could be due to the 1013 
use of different estrogenic activity assays (i.e. gene reporter assay in studies on Inuits, E-screen 1014 
assay in the study on Faroese women). Finally, the EDC biomarker highlighted some possible 1015 
associations between EDC exposure and diseases (i.e. breast cancer in Spanish women, child 1016 
adverse health effects).  1017 
In conclusion, the estrogenic activity on biological samples may have numerous applications 1018 
and, depending on the methodology used, it can provide different information: 1019 
i) It can be applied as a new method to quantify low levels of E2 in biological samples 1020 
and for this purpose it should be applied extracting the biological sample; 1021 
42 
 
ii) It can be applied to evaluate the estrogenic status providing considerable insight into 1022 
both physiological and pathological human conditions and for this purpose it should be 1023 
applied without any treatment.  1024 
iii) It can be applied to evaluate the presence of EDCs in biological samples and for this 1025 
purpose it should be applied using a separation technique, which allows the separation 1026 
of endogenous estrogens from xenoestrogens. 1027 
iv) It can be applied to evaluate the presence of specific categories of EDCs (such as 1028 
PFAAs) in biological samples and for this purpose the analytical techniques should be 1029 
chosen according to the chemical characteristics of the EDCs investigated. 1030 
v) It can be applied to assess the combined effect of endogenous estrogens and 1031 
xenoestrogens in biological samples and for this purpose it should be applied without 1032 
any separation technique. 1033 
Therefore, the choice of methodology implies the evaluation of the research aim and the 1034 
definition of the estrogenic activity as a biomarker of estrogenic status or EDC exposure. 1035 
Studies using this kind of biomarker are still limited in number; however, considering its 1036 
promising applications, future research is needed in this field in order to improve the 1037 
standardization of the different methods. 1038 
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11. Table captions 1426 
Table 1. Studies applying estrogenic activity assay as estrogen quantification and/or biomarker 1427 
of estrogenic status. 1428 
Footnotes:  1429 
AroER tri-screen cells = breast cancer MCF-7 variant without endogenous ER expression (C4-1430 
12) transfected with these plasmids: pTomo-ERα vector or pTomo-ERβ vector, pCHGP-2, 1431 
pCMV-G, pCMV-rev, pGL4.26 [luc2/minP/Hygro] (ERE)3. 1432 
Arxula adeninivorans = strain G1212 transformed with YRC102-hER-DsRed2 plasmid. 1433 
ERα CALUX cells = human osteoblastic osteosarcoma cells (U2-OS) transfected with 3x ERE-1434 
TATA-Luc and pSG5-neo-hERα (Wong et al. 2007). 1435 
HeLa transfected = human uterine cervix carcinoma cells (HeLa) stably transfected with 1436 
pERE4-Luchygro and pEGFP-ERαneo or pEGFP-ERβneo (HeLa ERα transfected or HeLa ERβ 1437 
transfected, respectively).  1438 
HELN = human uterine cervix carcinoma cells (HeLa) stably transfected with ERE-βGlob-1439 
Luc-SVNeo and pSG5ERαpuro or pSG5ERβpuro plasmids (HELNα or HELNβ, respectively).  1440 
MELN = breast cancer cells (MCF-7) stably transfected with ERE-βGlob-Luc-SVNeo plasmid.  1441 
Saccharomyces cerevisiae = strain BJ3505 (MATa, ura3-52, tryp1Δ101, lys2-208) transformed 1442 
with YEPKB1 and YRPE2 plasmids. 1443 
Saccharomyces cerevisiae_1 = triply deleted pdr5 snq2 yor 1 strain transformed with hERα-1444 
ERE-GFP or hERβ-ERE-GFP plasmids (Hasenbrink et al. 2006). 1445 
T47D-Kbluc = human breast cancer cells (T-47D) transfected with pGL2.TATA.Inr.luc.neo 1446 






Table 2. Studies applying estrogenic activity assay as a biomarker of exposure to EDCs. 1451 
Footnotes:  1452 
BG1Luc4E2 = human ovarian carcinoma cells (BG1) stably transfected with pGudLuc7.0 1453 
(Rogers and Denison 2000). 1454 
ERα CALUX cells = human osteoblastic osteosarcoma cells (U2-OS) transfected with 3x ERE-1455 
TATA-Luc and pSG5-neo-hERα (Wong et al. 2007). 1456 
MCF-7 transfected = breast cancer cells (MCF-7) transfected with ERE-tk109 luc, ERE2- 1457 
tk109 luc, ERE-tk81 luc. 1458 
MVLN = breast cancer cells (MCF-7) stably transfected with pVit-tk-Luc and pAG-60 1459 
plasmids (Pons et al. 1990). 1460 
Saccharomyces cerevisiae_2 = yeast genome integrated with human ER and transformed with 1461 
plasmid carrying the reporter gene lac-Z (plasmid code not specified) (Routledge and Sumpter 1462 
1996). 1463 
T47D.Luc = human breast cancer cells (T-47D) stably transfected with pEREtataLuc. 1464 
 1465 
Table 3. Characteristics of assays for the assessment of estrogenic activity in human biological 1466 
samples (Mueller 2004, Kiyama and Wada-Kiyama 2015, Seifert et al. 1999, Soto et al. 2006, 1467 
Wangmo et al. 2018, Wagner et al. 2017). Abbreviations of mammalian and yeast cells reported 1468 
in table 1 and table 2 (footnotes). 1469 
 1470 
Table 4. Detection limits of estrogenic activity assays compared to detection limits of direct 1471 
methods for estrogen quantification. Data are expressed as sensitivity for measuring 1472 
estrogens/progestagens (direct methods) and as sensitivity for measuring E2 (estrogenic 1473 
activity assays). Ns = not specified. Quantitation limits of direct methods for estrogen 1474 
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quantification are reported in table S.1 (Supplementary Material). Abbreviations of mammalian 1475 
and yeast cells reported in table 1 and table 2 (footnotes). 1476 
